Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.78 |
| ▸ | TGFB2 | P61812 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29977977 | 0.88 | TGFBR1 (1.00) | TGFBR1TGFB2 | |
| SCHEMBL2010521 | 0.88 | TGFBR1 (1.00) | TGFBR1TGFB2 | |
| SCHEMBL29978401 | 0.88 | TGFBR1 (1.00) | TGFBR1TGFB2RECQL | |
| SCHEMBL2009808 | 0.88 | TGFBR1 (1.00) | TGFBR1TGFB2RECQL | |
| SCHEMBL25942526 | 0.73 | TGFBR1 (0.62) | TGFBR1 | |
| SCHEMBL2012664 | 0.72 | TGFBR1 (0.52) | TGFBR1GRM5RECQLKDM4E | |
| SCHEMBL25942605 | 0.71 | TGFBR1 (0.55) | TGFBR1RECQL | |
| SCHEMBL25942657 | 0.70 | TGFBR1 (0.59) | TGFBR1 | |
| SCHEMBL24095516 | 0.70 | TGFBR1 (0.49) | TGFBR1GRM5RECQLKDM4ESMN1; SMN2 | |
| SCHEMBL25942612 | 0.70 | TGFBR1 (0.52) | TGFBR1RECQLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031385-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | Medicis Phamaceutical Corporation (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031385-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885TGFB2 7/4885GRM5 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.